- Home
- Products
- Customized ADCs
- Fibrin II-beta Chain
- Anti-Fibrin II-beta chain (Biciromab)-SMCC-DM1 ADC
Anti-Fibrin II-beta chain (Biciromab)-SMCC-DM1 ADC (CAT#: ADC-W-1994)
This ADC product is comprised of an anti-Fibrin II-beta chain Fab' fragmentconjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- Fibrin II-beta chain
- Alternative Names
- Fibrin II-beta chain
- Overview
- Fibrin (also called Factor Ia) is a fibrous, non-globular protein involved in the clotting of blood. It is formed from fibrinogen by the protease thrombin, and is then polymerised to form a "mesh" that forms a hemostatic plug or clot (in conjunction with platelets) over a wound site.Fibrin is involved in signal transduction, blood coagulation, and platelet activation.
- Overview
- Humanized Anti-Fibrin II-beta chain IgG1-Fab' fragment , Biciromab
- Generic name
- Biciromab
- Host animal
- Mouse
- Name
- SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IL13 (Anrukinzumab)-SMCC-DM1 ADC (CAT#: ADC-W-1298)
- Anti-CEACAM1 (Arcitumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-967)
- Anti-CD74-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2552)
- Anti-MET (Onartuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1543)
- Anti-ITGA2 (Vatelizumab)-MC-MMAF ADC (CAT#: ADC-W-1456)
- Anti-HBV surface antigen (Libivirumab)-MC-MMAF ADC (CAT#: ADC-W-1972)
- Anti-PCSK9 MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1685)
- Anti-CD79b (clone ch2F2)-SMCC-DM1 ADC (CAT#: ADC-W-168)
- Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2118)
- Anti-IL13 (Anrukinzumab)-MC-MMAF ADC (CAT#: ADC-W-1300)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1994. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1997 | Anti-Fibrin II-beta chain (Biciromab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-1998 | Anti-Fibrin II-beta chain (Biciromab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-1996 | Anti-Fibrin II-beta chain (Biciromab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-1995 | Anti-Fibrin II-beta chain (Biciromab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-1999 | Anti-Fibrin II-beta chain (Biciromab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
CAT# | Product Name | Linker | Payload |
ADC-W-603 | Anti-FOLH1 (clone J591)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2583 | Anti-EGFR (Zalutumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2571 | Anti-SLC34A2 (Lifastuzumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2589 | Anti-EGFR (Cetuximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-479 | Anti-CD74-SMCC-Dox ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
CAT# | Product Name | Linker | Payload |
ADC-W-2548 | Anti-CD74-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2598 | Anti-GPNMB (Glembatumumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2554 | Anti-CD79B (Polatuzumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2589 | Anti-EGFR (Cetuximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2604 | Anti-ITGB3 (Tadocizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.